Pirfenidone Dosing
The standard maintenance dose of pirfenidone is 2,403 mg/day (801 mg three times daily with food), achieved through gradual dose titration over 14 days, with dose modifications required for hepatic impairment and cautious use in renal impairment. 1
Standard Dosing Schedule
The recommended dosing follows a structured titration protocol:
- Days 1-7: 267 mg three times daily (801 mg/day total)
- Days 8-14: 534 mg three times daily (1,602 mg/day total)
- Day 15 onward: 801 mg three times daily (2,403 mg/day total - maintenance dose)
All doses must be taken with food to minimize gastrointestinal adverse effects. 2
While the standard 2-week titration is recommended, real-world practice shows that alternative titration schedules up to 4-8 weeks are commonly employed when patients experience gastrointestinal intolerance, with most patients ultimately achieving full dose. 3 Taking pirfenidone during a substantial meal (not just a snack) is the most effective strategy for mitigating GI adverse events. 3
Dose Adjustments for Hepatic Impairment
Mild to moderate hepatic impairment (Child-Pugh Class A or B):
- Use with caution
- Monitor closely for adverse reactions
- Consider dose modification or temporary discontinuation as needed
- Perform liver function tests before initiation, then monthly for 6 months, then every 3 months thereafter 2, 1
Severe hepatic impairment (Child-Pugh Class C):
- Pirfenidone is NOT recommended - contraindicated 1
The pharmacokinetics have not been studied in severe hepatic impairment, making use unsafe in this population.
Dose Adjustments for Renal Impairment
Mild (CrCl 50-80 mL/min), moderate (CrCl 30-50 mL/min), or severe (CrCl <30 mL/min) renal impairment:
- Use with caution
- Monitor for adverse reactions
- Consider dose modification or discontinuation as needed 1
End-stage renal disease requiring dialysis:
- Pirfenidone is NOT recommended 1
Recent evidence suggests that renal function may not significantly impact pirfenidone pharmacokinetics in CKD stages G2/G3a, with no significant differences in Cmax, Tmax, or half-life compared to normal renal function. 4 However, the FDA label maintains cautious recommendations pending further data.
Critical Contraindications and Warnings
Absolute contraindications:
Avoid or use with extreme caution:
- Omeprazole - may alter pirfenidone pharmacokinetics 2
- Smoking - significantly decreases pirfenidone exposure through CYP1A2 induction, potentially reducing efficacy. Patients must discontinue smoking before and during treatment. 1, 4
Monitoring Requirements
- Liver function tests: Baseline, then monthly × 6 months, then every 3 months 2
- Clinical tolerance monitoring: Ongoing assessment for GI effects, photosensitivity, rash, fatigue 2
- UV exposure counseling: Warn patients about photosensitivity and recommend sun protection measures 2
Practical Considerations
Real-world data indicates that only about 21% of patients tolerate the full 2,400 mg dose, with 1,200 mg/day being the most commonly tolerated dose. 5 Patients who are male, taller, and have larger body surface area demonstrate better tolerability. 5 However, efficacy data at reduced doses remains limited, creating uncertainty about the therapeutic benefit of dose reductions. 6
No dose adjustment is required based on age alone, despite the elderly population comprising the majority of IPF patients. 1